Clinical trial pay now tax-free, protecting low-income participants
S. 5127 — Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026 · Filed by Jim Banks (R-IN) · 1 cosponsor · Introduced Jul 23, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill exempts compensation paid to clinical trial participants from federal income tax and excludes it from counting as income when determining eligibility for federal assistance programs (like Medicaid, SNAP, housing assistance). Participants can receive payment for their time and reimbursement for trial-related expenses without triggering tax liability or losing benefits.
Why we flagged it
The bill's operative mechanism is a tax and benefit-eligibility exemption designed to remove financial disincentives for clinical trial participation. It is not a general tax cut or subsidy to industry, but rather a targeted removal of a penalty on individual participants.
What the text implies
- Pharmaceutical and biotech companies may benefit indirectly by reducing recruitment friction for trials, potentially lowering trial costs and accelerating enrollment — a private benefit not explicitly stated in the bill's civic framing.
- The exemption applies retroactively to payments made after December 31, 2025, creating a tax-filing adjustment window that may require IRS guidance and administrative burden.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies; biotech firms; contract research organizations (CROs)